Hatch-Waxman 2023 Year in Review


Watch Replay and Access Slides

Nearly 40 years ago, Congress signed into law the Hatch-Waxman Act, balancing the need for lower cost prescription drugs and the protection of pharmaceutical innovations. For both branded and generic drug developers, the Hatch-Waxman legal landscape continues to evolve through decisions by courts, the U.S. Food and Drug Administration, and the U.S. Patent and Trademark Office.

On December 7, 2023, please join Principals Christina Brown-Marshall and Megan Chacon for an overview of the Hatch-Waxman landscape in 2023. Discussion topics will include:

  • Who, what, and where: Hatch-Waxman litigation trends
  • Key 2023 cases: takeaways and strategy considerations
  • Government agency impact: updates on FDA, USPTO, and Federal Trade Commission actions
  • Looking ahead: what to keep an eye out for in 2024​

If you have any questions, please contact [email protected].